Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma plc (RPRX), sold 130,000 shares at $56.50 ($7.3M) on 2026-06-30, disclosed to the SEC on 2026-07-02.
Scheduled sale ($7.3M) by EVP & Chairman, Partnering under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.44 | 29,400 | $1.7M | 22.6% |
| 2 | $56.50 | 97,446 | $5.5M | 75.0% |
| 3 | $57.09 | 600 | $34K | 0.5% |
| 4 | $57.10 | 2,554 | $146K | 2.0% |
| Total | $56.50 avg | 130,000 | $7.3M | 100% |
| Filing → |
| RPRX | SELL | 2026-06-25 | $8.2M | — | Filing → |
| RPRX | BUY | 2020-06-23 | $2.0M | — | Filing → |